Skip to main content

Table 2 Patient characteristics

From: A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine

  Pregabalin Duloxetine  
  N = 446 N = 446  
  n % n % P value*
Age, years (categorical)      0.1304
18-29 0 0.0 0 0.0  
30-39 7 1.6 1 0.2
40-49 27 6.1 26 5.8
50-59 73 16.4 86 19.3
60-69 144 32.3 159 35.7
70-79 150 33.6 126 28.3
80-89 45 10.1 48 10.8
Gender      0.5854
Male 185 41.5 177 39.7  
Female 261 58.5 269 60.3
Race/Ethnicity      0.7265
White 363 81.4 353 79.1  
Black 58 13.0 69 15.5
Hispanic 13 2.9 14 3.1
Other 12 2.7 10 2.2
Geographic Region      0.6759
Northeast 5 1.1 5 1.1  
Midwest 78 17.5 78 17.5
South 338 75.5 333 74.7
West 25 5.6 30 6.7
Low Income Status 87 19.5 92 20.6 0.6814
Dual Eligibility Status 52 11.7 56 12.6 0.6759
  Mean SD Mean SD  
Age, years (continuous) 66.7 10.7 66.7 10.4 0.5924
Propensity Score 0.47 0.14 0.47 0.14 0.9931
  1. *All P values for categorical variables calculated using chi -square tests. All P values for continuous variables calculated using Wilcoxon rank-sum tests.
  2. SD, Standard Deviation.